Feasibility of the adoptive transfusion of allogenic human leukocyte antigen-matched natural killer cells in patients with renal cell carcinoma.
Patients with metastasized renal cell carcinoma have a poor prognosis with conventional therapies. The feasibility and safety of donating purified natural killer (NK) cells without additional cytokines were evaluated. In contrast to all previous studies, the NK cells were derived from allogenic donors. The NK cell donors were HLA-C matched to enable NK cell inhibition via killer cell inhibitory receptors and HLA-C. This should obviate a graft-versus-host reaction against nonmalignant HLA-expressing tissues in the allogenic constellation. The average number of cells applied per transfusion was 1.02 +/- 0.265 x 10(9). The purity of the NK cells was 85% to 95%, and most of the contaminating cells were monocytes. Twenty-six transfusions given to 11 patients did not cause any minor or major adverse effects, with the exception of one episode of transient fever. One patient had an objective regression of his lung metastases that had been progressing continuously before. No cytotoxic HLA antibodies could be detected 3 weeks after the transfusions. The observed tolerance to this therapeutic regimen suggests the need for further studies with increased doses of cytokine-activated NK cells.
Frohn
C
C
Institute of Immunology and Transfusion Medicine, University of Lübeck School of Medicine, Germany.
Doehn
C
C
Durek
C
C
Böhle
A
A
Schlenke
P
P
Jocham
D
D
Kirchner
H
H
D019264:Adoptive Transfer / Q000009:adverse effects / Q000379:methods*; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D005240:Feasibility Studies; D015236:HLA-C Antigens / Q000276:immunology*; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*; D007694:Killer Cells, Natural / Q000276:immunology* / Q000637:transplantation*; D018655:Lymphocyte Count; D008875:Middle Aged; D009362:Neoplasm Metastasis
D015703:Antigens, CD; D015236:HLA-C Antigens